drugset / Trial / NCT01230138

Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis

NCT01230138

Phase 2 Completed 252 enrolled Forward-Pharma GmbH
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this trial is to investigate the efficacy and safety of different doses and dose administrations of FP187 compared to a placebo treatment in patients with moderate to severe plaque psoriasis.

Timeline

Start
2010-09
Primary completion
2012-01
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject FP187 Unknown 250 mg Oral
Subject FP187 Unknown 375 mg Oral

Indications